Page 9 - Array Biopharma News Today

Latest research on Global Breast Cancer Monoclonal Antibodies Market report covers forecast and analysis on a worldwide, regional and country level. T

Defendants. This notice is for all persons or entities who purchased or otherwise acquired Array Biopharma, Inc. Common Stock between June 30, 2016 and March 17, 2017, inclusive (the "Class").   YOU ARE HEREBY NOTIFIED that pursuant to an Order of the United States District Court for the District of Colorado, a hearing will be held on October 29, 2021, at 2:30 p.m., before the Honorable Kristen L. Mix, United States District Judge, at the Courthouse for the United States District Court, Distr...

Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns, JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $230.7 million in cash, sufficient to fund operations into 2024 News provided by Share this article Share this ar...

The ongoing pandemic has created a wealth of interest from venture capital investors and the broader public in what biotech companies are able to achieve if it’s flush with resources. That was the sentiment of a group of Boulder area biotechnology industry leaders, who met virtually at BizWest’s CEO Roundtable on the biotechnology industry Tuesday morning. Steady stream of investor dollars Biotech was one of the few industries that was relatively unaffected from a financial standpoint durin...

DENVER — The Colorado Bioscience Association said the state’s biotech industry set a record for new venture funding in the first quarter of 2021, with a lion’s share of those dollars coming from Boulder-area companies. The trade association said Tuesday that biotech companies in the state raised $704 million in the last quarter. That figure is more than half of the $1.2 billion in venture funding issued in the entirety of 2020 and well on its way toward eclipsing the $850 million or so is...

[co-author: Sarah Taheny] The European Commission (EC) has published new guidance on the application of Article 22 of the European Merger Regulation (EUMR) which will allow for the EC and Member States to refer transactions that do not meet existing EC or national jurisdictional thresholds for EC review. On March 26, 2021, the EC published its Staff Working Document (Working Document) on the Evaluation of Procedural and Jurisdictional Aspects of EU Merger Control, 1 the latest step in its evalu...

Tyler Jacks, Ph.D., after 19 years. The director role will be taken over by Matthew Vander Heiden, M.D., Ph.D., a professor of biology at MIT and a medical oncologist at Dana-Farber Cancer Institute. He became a member of the Koch Institute in 2010 and took over for Jacks on Thursday, MIT said. Jacks will continue to lead the Bridge Project, which unites bioegnineers, cancer scientists and clinical oncologists from the Koch Institute and the Dana-Farber/Harvard Cancer Center. > Atara Bioth...

Published: Apr 09, 2021 By Alex Keown Atara Biotherapeutics – Amie Krause was named Senior Vice President and Chief People Officer at Atara Biotherapeutics. In this role, Krause will be tasked with building a company culture that “rewards” values through actions and results. Prior to her tenure with Atara, Krause held several HR leadership positions at Amgen, including her role as Global HR Lead, Organizational Effectiveness during which she served as the human resources lead for...

Cogent Biosciences Announces Creation of Cogent Research Team Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21 News provided...

BOULDER — Cogent Biosciences Inc. (Nasdaq: COGT) hired former Array Biopharma research leader John Robinson as its chief scientific officer, and said it will house a team of researchers in Boulder. In a statement, Cambridge, Massachusetts-based Cogent said it plans to initially hire eight researchers in a rented laboratory space in north Boulder but eventually plans to build its own dedicated facility to house up to 50 researchers. Robinson will lead the new team from Boulder after spending t...